Patents Assigned to Bruker Cellular Analysis, Inc.
-
Patent number: 12138626Abstract: In situ-generated microfluidic isolation structures incorporating a solidified polymer network, methods of preparation and use, compositions and kits therefor are described. The ability to introduce in real time, a variety of isolating structures including pens and barriers offers improved methods of micro-object manipulation in microfluidic devices. The in situ-generated isolation structures may be permanently or temporarily installed.Type: GrantFiled: February 3, 2023Date of Patent: November 12, 2024Assignee: BRUKER CELLULAR ANALYSIS, INC.Inventors: Kristin G. Beaumont, Nan-Linda Ding, Volker L. S. Kurz, Troy A. Lionberger, Randall D. Lowe, Jr., Daniele Malleo, Andrew W. McFarland, J. Tanner Nevill, Xiaohua Wang
-
Patent number: 12134758Abstract: Systems, methods and kits are described for culturing one or more biological cells in a microfluidic device, including provision of nutrients and gaseous components configured to enhance cell growth, viability, portability, or any combination thereof. In some embodiments, culturing a single cell may produce a clonal population in the microfluidic device.Type: GrantFiled: May 12, 2022Date of Patent: November 5, 2024Assignee: BRUKER CELLULAR ANALYSIS, INC.Inventors: Randall D. Lowe, Jr., Kristin G. Beaumont, Aathavan Karunakaran, Natalie C. Marks, Jason M. McEwen, Mark P. White, J. Tanner Nevill, Gang F. Wang, Andrew W. McFarland, Daniele Malleo, Keith J. Breinlinger, Xiao Guan, Kevin T. Chapman
-
Publication number: 20240342704Abstract: Proto-antigen-presenting surfaces and related kits, methods, and uses are provided. The proto-antigen-presenting surface can comprise a plurality of primary activating molecular ligands comprising a major histocompatibility complex (MHC) molecule configured to bind to a T cell receptor (TCR) of a T cell and a plurality of co-activating molecular ligands each including a TCR co-activating molecule or an adjunct TCR activating molecule, wherein an exchange factor is bound to the MHC molecules. Exchange factors include, e.g., dipeptides such as GL, GF, GR, etc. Proto-antigen-presenting surfaces can be used to rapidly prepare antigen-presenting surfaces comprising one or more peptide antigens of interest by contacting the proto-antigen-presenting surface with one or more peptide antigens so as to displace the exchange factor. As such, the disclosure facilitates rapid evaluation of the immunogenicity of peptide antigens for activating T lymphocytes.Type: ApplicationFiled: November 9, 2023Publication date: October 17, 2024Applicant: Bruker Cellular Analysis, Inc.Inventors: Peter J. Beemiller, Alexander J. Mastroianni, Shao Ning Pei, Randall D. Lowe, Jr., Annamaria Mocciaro, Kevin D. Loutherback, Yelena Bronevetsky, Guido K. Stadler, Andrew W. McFarland, Kevin T. Chapman, Duane Smith, Natalie C. Marks, Amanda L. Goodsell
-
Patent number: 12102083Abstract: A method of processing and storing biological cells includes introducing a flowable medium into a microfluidic device, the flowable medium including biological cells; sequestering one or more biological cells from the flowable medium in one or more isolation regions of the microfluidic device; and freezing the microfluidic device including the one or more biological cells sequestered therein.Type: GrantFiled: April 12, 2021Date of Patent: October 1, 2024Assignee: BRUKER CELLULAR ANALYSIS, INC.Inventors: Mark P. White, Kevin T. Chapman, Andrew W. McFarland, Eric D. Hobbs, Randall D. Lowe, Jr.
-
Publication number: 20240318120Abstract: Methods, systems, and kits for determining a level of dissolved oxygen within a microfluidic device are provided. The microfluidic device can be suitable for cell culture. The methods, systems, and kits can further be used to determine a level of oxygen consumption in a population of biological micro-objects. In particular, the methods, systems, and kits of the present disclosure rely on flowing a fluidic medium containing a dye and a supplied partial pressure of oxygen into the microfluidic device for a period of time, wherein fluorescence emitted by the dye changes based on availability of oxygen proximate to the dye; taking a fluorescence image of an area of interest within the chamber; and correlating fluorescence of the fluorescence image of the area of interest to a reference to determine an observed partial pressure of the oxygen in the area of interest.Type: ApplicationFiled: August 30, 2021Publication date: September 26, 2024Applicant: BRUKER CELLULAR ANALYSIS, INC.Inventors: Patrick N. INGRAM, Alexander CHIEN, Ke-Chih LIN, Or GADISH, Troy A. LIONBERGER, Eric K. SACKMANN, Volker L.S. KURZ, Alexander J. MASTROIANNI, Randall D. LOWE, JR., Jonathan Cloud Dragon HUBBARD
-
Publication number: 20240302378Abstract: Metabolic engineering has developed microbial cell factories as sustainable alternatives to chemical synthesis from petroleum feedstocks or harvesting of animals and plants, but current methods can be a costly and labor-intensive commitment. Methods are described herein for microfluidic methods of screening thousands of variant cells in order to reduce time and uncertainty to provide improved strains.Type: ApplicationFiled: October 5, 2023Publication date: September 12, 2024Applicant: Bruker Cellular Analysis, Inc.Inventors: Or Gadish, Kellen C. Mobilia, Sara Tafoya, Eric K. Sackmann, Alexander J. Mastroianni, Peyton Shieh, Smriti Sridhar, Pierre Sphabmixay, Eva Y. Cheung, Grayson T. Wawrzyn, Long V. Le, Nathan J. Ver Heul, Bo Hu, Lily Chao, Ke-Chih Lin, Volker L.S. Kurz, Robert M. Onorato
-
Patent number: 11998914Abstract: Biological activity in holding pens in a micro-fluidic device can be assayed by placing in the holding pens capture objects that bind a particular material of interest produced by the biological activity. The biological material of interest that binds to each capture object can then be assessed, either in the micro-fluidic device or after exporting the capture object from the micro-fluidic device. The assessment can be utilized to characterize the biological activity in each holding pen. The biological activity can be production of the biological material of interest. Thus, the biological activity can correspond to or arise from one or more biological cells. Biological cells within a holding pen can be clonal cell colonies. The biological activity of each clonal cell colony can be assayed while maintaining the clonal status of each colony.Type: GrantFiled: March 24, 2022Date of Patent: June 4, 2024Assignee: BRUKER CELLULAR ANALYSIS, INC.Inventors: Kevin T. Chapman, Daniele Malleo, J. Tanner Nevill, Steven W. Short, Mark P. White, M. Jimena Loureiro
-
Patent number: 11999992Abstract: Reagents for stabilizing the nucleic acids of a biological cell, compositions, kits and methods of use thereof are described. The stabilization reagents may prepare the nucleic acids within the biological cell for storage and preserve the representative population of the nucleic acids for later isolation and analysis.Type: GrantFiled: September 13, 2018Date of Patent: June 4, 2024Assignee: Bruker Cellular Analysis, Inc.Inventor: Jason M. McEwen
-
Patent number: 11993766Abstract: In biosciences and related fields, it can be useful to modify surfaces of apparatuses, devices, and materials that contact biomaterials such as biomolecules and biological micro-objects. Described herein are surface modifying and surface functionalizing reagents, preparation thereof, and methods for modifying surfaces of wells within a well plate to activate lymphocytes, including but not limited to T lymphocytes, in a controllable and reproducible manner.Type: GrantFiled: September 20, 2019Date of Patent: May 28, 2024Assignee: BRUKER CELLULAR ANALYSIS, INC.Inventors: Peter J. Beemiller, Alexander J. Mastroianni, Randall D. Lowe, Jr., Yelena Bronevetsky
-
Patent number: 11971409Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.Type: GrantFiled: June 4, 2020Date of Patent: April 30, 2024Assignee: Bruker Cellular Analysis, Inc.Inventors: Kevin T. Chapman, Mark P. White, Xiaohua Wang, Minha Park, Guido K. Stadler, Randall D. Lowe, Jr., Xiao Guan Radstrom, Jason M. McEwen, Gang F. Wang, George L. Fox, Peggy A. Radel
-
Patent number: D1051184Type: GrantFiled: October 20, 2022Date of Patent: November 12, 2024Assignee: Bruker Cellular Analysis, Inc.Inventors: Raziel Solomon Alon, Angel Navas Angeles, Ken Huynh, Christopher C. Shing
-
Patent number: D1051185Type: GrantFiled: October 20, 2022Date of Patent: November 12, 2024Assignee: Bruker Cellular Analysis, Inc.Inventors: Raziel Solomon Alon, Angel Navas Angeles, Ken Huynh, Christopher C. Shing, David Aaron Weisbach